-Galactosidase replacement therapy in Fabry's disease

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1303, 2001-01, pp. : 2-2

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Enzyme Replacement Therapy in Patients with Fabry's Disease

By Tsuboi K  

The Journal of International Medical Research, Vol. 35, Iss. 4, 2007-07 ,pp. : 574-581

Field House Publishing

Access to resources Recommend Favorite

Fabry disease: recent advances in enzyme replacement therapy

By Germain Dominique P  

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 10, 2002-10 ,pp. : 1467-1476

Informa Healthcare

Access to resources Recommend Favorite

Enzyme Replacement Therapy for Fabry Disease: A Systematic Review of Available Evidence

By Schaefer Roland M.  

Drugs, Vol. 69, Iss. 16, 2009-11 ,pp. : 2179-2205

Adis International

Access to resources Recommend Favorite

Agalsidase alfa – a preparation for enzyme replacement therapy in Anderson–Fabry disease

By Beck Michael  

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 6, 2002-06 ,pp. : 851-858

Informa Healthcare

Access to resources Recommend Favorite

Enzyme Replacement Therapy in Orphan and Ultra-Orphan Diseases: The Limitations of Standard Economic Metrics as Exemplified by Fabry-Anderson Disease

By Moore David F.  

PharmacoEconomics, Vol. 25, Iss. 3, 2007-01 ,pp. : 201-208

Adis International

Access to resources Recommend Favorite